Many people with inflammatory bowel disease (IBD) experience bloating, cramping, and unpredictable bowel habits even when their disease is in remission. These symptoms can feel identical to an active flare, leading to confusion about whether inflammation has returned. The low-FODMAP diet has become popular for managing these persistent gut symptoms, but its role in IBD is more nuanced than many realise.
What Are FODMAPs?
FODMAP stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. These short-chain carbohydrates are poorly absorbed in the small intestine. When they reach the colon, gut bacteria ferment them rapidly, producing gas and drawing water into the bowel. This triggers symptoms such as bloating, abdominal pain, diarrhoea, and urgency.
Common high-FODMAP foods include wheat, onions, garlic, apples, pears, milk, yoghurt, beans, lentils, and sugar alcohols in some sugar-free products. The low-FODMAP diet restricts these foods temporarily to assess whether they contribute to symptoms.
Why Symptoms Do Not Always Mean Inflammation
It is important to distinguish between functional gut symptoms and active inflammation. Many people with IBD in remission continue experiencing discomfort that mirrors a flare but is not driven by immune activity or mucosal damage. This overlap can be caused by changes in gut motility, visceral hypersensitivity, or alterations in the gut microbiome following inflammation.
Objective markers such as faecal calprotectin, C-reactive protein, or endoscopy are needed to confirm whether inflammation is present. Symptoms alone are unreliable indicators, and treating functional symptoms with anti-inflammatory therapy is unlikely to help.
The Evidence for Low-FODMAP in IBD
Research has focused primarily on irritable bowel syndrome (IBS), where the diet reduces symptoms in around 70 per cent of people. Studies in IBD populations are smaller but suggest it may help some individuals, particularly those with inactive disease who continue experiencing IBS-like symptoms.
One study found that people with quiescent Crohn’s disease or ulcerative colitis following a low-FODMAP diet reported significant improvements in bloating, pain, and bowel frequency. However, these were symptom-based outcomes, not measures of inflammation. The diet did not influence disease activity or mucosal healing.
The benefit appears greatest in those with overlapping functional symptoms rather than active inflammation, highlighting the importance of accurate diagnosis before starting dietary restriction.
How the Low-FODMAP Diet Works
The diet has three phases: restriction, reintroduction, and personalisation.
Restriction Phase
High-FODMAP foods are eliminated for four to six weeks. This is not permanent. The goal is to reduce fermentation in the colon and assess whether symptoms improve. Maintaining variety and nutritional adequacy is important, particularly for fibre, calcium, and other nutrients that may be reduced.
Reintroduction Phase
Individual FODMAP groups are tested one at a time to identify which types trigger symptoms and at what dose. This phase is essential and should be guided by a dietitian with IBD experience. Without reintroduction, the diet remains unnecessarily restrictive and risks nutritional deficiency and negative effects on the gut microbiome.
Personalisation Phase
Based on reintroduction results, a tailored diet is developed that avoids only specific FODMAPs causing symptoms. Most people can tolerate some FODMAPs in moderate amounts, and this phase restores flexibility and variety.
Potential Risks in IBD
Whilst the low-FODMAP diet can be effective for symptom management, it carries risks, particularly in IBD populations.
Nutritional Deficiency
Many high-FODMAP foods are nutrient-dense, including wholegrains, legumes, and certain fruits and vegetables. Prolonged restriction without proper guidance can lead to inadequate intake of fibre, B vitamins, calcium, magnesium, and prebiotics that support gut health.
Microbiome Changes
The gut microbiome thrives on dietary fibre and fermentable substrates. Research shows the low-FODMAP diet can reduce beneficial bacteria such as Bifidobacteria, which play a role in immune regulation and gut barrier function. In people with IBD, who often already have reduced microbial diversity, this is a significant concern.
Psychological Impact
Food restriction can increase food-related anxiety and reduce quality of life, particularly if followed long term without reintroduction. This is especially relevant in IBD, where many already navigate dietary uncertainty and fear around eating.
Who Might Benefit?
The low-FODMAP diet is not appropriate for everyone with IBD. It is most likely helpful for people who meet these criteria:
- Confirmed remission or low disease activity, verified by objective markers such as faecal calprotectin or endoscopy.
- Persistent symptoms resembling IBS, including bloating, cramping, and altered bowel habits.
- No evidence of active inflammation or significant structural complications such as strictures.
- Access to support from a registered dietitian with experience in both IBD and FODMAP protocols.
It is not a first-line approach for active disease and does not treat inflammation. If symptoms are accompanied by blood in the stool, weight loss, fever, or fatigue, medical review is essential before considering dietary intervention.
Practical Takeaways
- Confirm disease activity with your healthcare team before starting a low-FODMAP diet. Symptoms do not always reflect inflammation.
- Work with a dietitian who understands IBD. The restriction phase is only the beginning; reintroduction is essential.
- Plan for four to six weeks of elimination, followed by structured reintroduction over several weeks.
- Do not remain on a restricted diet long term. Personalisation is the goal.
- Monitor nutritional intake, particularly fibre, calcium, and variety.
- Keep a symptom and food diary to help identify patterns during reintroduction.
Conclusion
The low-FODMAP diet can be a useful tool for managing functional gut symptoms in people with IBD who are in remission. However, it is not a treatment for inflammation and is not suitable for everyone. Accurate diagnosis, professional guidance, and commitment to the full reintroduction process are essential to avoid unnecessary restriction and preserve gut health. When used appropriately, the diet can offer meaningful symptom relief and improve quality of life without compromising long-term nutritional or microbial balance.
References
- Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75. doi:10.1053/j.gastro.2013.09.046
- Cox SR, Prince AC, Myers CE, et al. Fermentable carbohydrates [FODMAPs] exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial. J Crohns Colitis. 2017;11(12):1420-1429. doi:10.1093/ecco-jcc/jjx073
- Gearry RB, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease: a pilot study. J Crohns Colitis. 2009;3(1):8-14. doi:10.1016/j.crohns.2008.09.004
- Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-1527. doi:10.1136/gutjnl-2017-313750
- Staudacher HM, Lomer MCE, Farquharson FM, et al. A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores Bifidobacterium species: a randomized controlled trial. Gastroenterology. 2017;153(4):936-947. doi:10.1053/j.gastro.2017.06.010
- O’Keeffe M, Jansen C, Martin L, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(1):e13154. doi:10.1111/nmo.13154
- Hustoft TN, Hausken T, Ystad SO, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017;29(4):e12969. doi:10.1111/nmo.12969
- Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet. 2018;31(2):239-255. doi:10.1111/jhn.12530
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.